Exelixis
EXEL
$21.02
Share price
-0.47%
Change (1 day)
7.79%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Exelixis (EXEL) Fails to deliver data
Key failure to deliver metrics for Exelixis:
- Last SEC data release: 2024-04-30
- Last 15 days FTD volume: $0.01 M
- Last 3 months FTD volume: $0.67 M
- Last year FTD volume: $5.68 M
Failures to deliver for Exelixis (EXEL) - 3 months history
Number of shares, 3 months chartBiweekly Failures to deliver volume for Exelixis (EXEL) - since 2013
Volume in USD (price x number of shares), data since 2013Exelixis (EXEL) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2024 | $0.84 M | -86.91% |
| 2023 | $6.48 M | -41.81% |
| 2022 | $11.14 M | -31.9% |
| 2021 | $16.36 M | -20.71% |
| 2020 | $20.64 M | 303.63% |
| 2019 | $5.11 M | -70.5% |
| 2018 | $17.33 M | 8.82% |
| 2017 | $15.92 M | -17.35% |
| 2016 | $19.27 M | -75.68% |
| 2015 | $79.23 M | 19.37% |
| 2014 | $66.37 M | 258.49% |
| 2013 | $18.51 M |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3months) | FTD volume (1 year) | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $0.13 B | $0.59 B | 🇺🇸 USA |
 Pfizer PFE | $10.32 M | $0.31 B | 🇺🇸 USA |
 Amgen AMGN | $52.25 M | $0.21 B | 🇺🇸 USA |
 Sanofi SNY | $21.22 M | $52.23 M | 🇫🇷 France |
 Merck MRK | $6.57 M | $0.15 B | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $0.23 B | $0.32 B | 🇺🇸 USA |
 GlaxoSmithKline GSK | $18.31 M | $24.09 M | 🇬🇧 UK |
 Curis CRIS | N/A | $0.95 M | 🇺🇸 USA |
 AVEO Oncology
AVEO | N/A | $0.04 M | 🇺🇸 USA |